Affimed N.V

Affimed N.V. is a clinical‑stage biotech developing CD30‑targeted immunotherapies like AFM13 (Phase II) and next‑generation ICE agents (AFM24, AFM28) for lymphoma and solid cancers, backed by Genentech and Roivant collaborations.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Biotechnology Research

Employees: 76
HQ: Mannheim

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
AFMD	Affimed N.V	EQUITY	NMS	USD	NL0010872420	Review	📈